Sign in

    Lucy De Yang • Raymond James

    No publicly available information could be found confirming Lucy De Yang's role as an analyst at Raymond James, nor details on specific company coverage, performance metrics, career timeline, or professional credentials. As such, a comprehensive professional profile with the requested details cannot be provided at this time.

    Lucy De Yang's questions to Lineage Cell Therapeutics Inc (LCTX) leadership

    Lucy De Yang's questions to Lineage Cell Therapeutics Inc (LCTX) leadership • Q1 2025

    Question

    Lucy De Yang of Raymond James asked for management's view on the new CDER director's stance on cell therapy and for specifics on the OPC1 spinal cord injury trial design.

    Answer

    CEO Brian Culley expressed confidence in the new FDA leadership, welcoming a high, data-driven bar that he believes will favor therapies like OpRegen with significant clinical benefits. He outlined the OPC1 trial as a single-arm study for 6-10 patients, with a staggered enrollment starting with three thoracic injury patients before moving to cervical injury patients.

    Ask Fintool Equity Research AI